SHR-A1921

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameSHR-A1921
Drug Alias NameSHR-A1921SHRA1921SHR-1921
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SHR9265 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Trop-2
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Suncadia Biopharmaceuticals Co LtdShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHenan Provincial Cancer HospitalShanghai Pulmonary HospitalBeijing GoBroad Hospital +[8] 
Inactive CompaniesN/A
Active IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[11] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A